Drug intelligence / Profile preview

GB-AF-001

Development stage: Preclinical
Lead developer: GAT Biosciences
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

GB-AF-001 is an investigational **oral biologic** developed by **GAT Biosciences** for the treatment and prevention of **SARS-CoV-2** infections. Functioning as a **neutralizing agent**, the candidate is designed to target the virus in both the respiratory and intestinal tracts, potentially offering a broad-spectrum approach to managing COVID-19. The drug is currently in the **preclinical** stage, with in vitro studies supporting its development as a convenient oral therapeutic option for respiratory and intestinal viral infections.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on GB-AF-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-AF-001.

Explore the full profile